

Revvity launches innovative reagent technology to accelerate therapeutics development

06 August 2025 | News

Innovative plate-based internalisation reagents designed to deliver accurate insights



US-based Revvity, Inc. has announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery.

pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalisation.

Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to-background—even at low endogenous receptor expression levels. Fully compatible with Revvity's multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows.

By enabling more efficient screening and characterisation of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation.

With a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design focused on addressing major limitations of current offerings such as low throughput and suboptimal signal-to-noise ratios.